'Key' to immunising herpes, common cold found

Image
Press Trust of India Toronto
Last Updated : Apr 11 2016 | 1:07 PM IST
Scientists have discovered a critical step in the immune system's recognition of DNA viruses, an advance that may lead to vaccinations for herpes, the common cold or even cancer.
A new study found that a protein, previously known to be involved in metabolism, is critical for the detection of the viruses.
The discovery is a significant advancement towards the development of vaccines for DNA viruses such as herpes and colds, researchers said.
"We have identified an important step in the detection of DNA viruses by the immune system, and have shown that this is absolutely crucial in the response to a vaccine against these infections," said Brian Lichty from McMaster University in Canada.
"If the key immune system component identified in these studies is not triggered, then vaccination fails," said Lichty.
This study could have further impact on a number of serious conditions and illnesses, researchers said.
"This represents a breakthrough in our fundamental understanding of how our immune system detects a viral infection," said Yonghong Wan from McMaster University.
"But it goes beyond that, as this component of our immune system is also involved in detection of cancer by our immune system and is central to the development of autoimmune diseases," Wan said.
"So this discovery potentially impacts anyone infected by a virus, receiving a vaccination, fighting cancer or experiencing autoimmunity," he added.
Prior to the study, it was known that interferon regulatory factor-3 (IRF-3), a protein coding gene, contributed to a first line of defense against viral infection by triggering antiviral activity. However the activation of IRF-3 following infection was not fully understood.
The study found that an interaction with the protein S6K1 and the signalling adaptor STING is a fundamental regulatory mechanism for IRF3 and, thus, helps trigger antiviral responses.
"Now that we have identified this aspect of the immune system, we can work on developing methods to engage this pathway during vaccination against viruses or cancer," Lichty added.
The findings were published in the journal Nature Immunology.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 11 2016 | 1:07 PM IST

Next Story